Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
Nils Wilking(Sophiahemmet Hospital), Jonas Bergh(Karolinska Institutet), Jonas Nilsson(Regional Research Council in Uppsala-Örebro Region), N-O Bengtsson(Umeå University), S. Ottosson(Sahlgrenska University Hospital), Carl Blomqvist(University of Helsinki), Annika Malmström(Lund University), Henrik Lindman(Uppsala University), Elisabet Lidbrink(Stockholm South General Hospital), Per Ljungman(Karolinska University Hospital), Harald Holte(Oslo University Hospital), Pirkko Kellokumpu‐Lehtinen(Tampere University Hospital), G Söderlund(Linköping University), Björn Erikstein, Eeva Salminen(University of Turku), Gun Anker(Haukeland University Hospital), E. Wist(Oslo University Hospital), Tom Wiklund(Lund University)
Cited by 36
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k